HOME PAGE
ABOUT ENEWSCHANNELS
OUR STAFF
Part of the Neotrope News Network


News Desk Columns Books Business Medical Music Software US Govt. RSS

SELECT TRIAL used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R)

Email this Page Print Page      Feedback      Social Media Options (click)
Sun, 02 Nov 2008 15:56:54 -0500 EST  |  No Comments

FRESNO, Calif. — Cypress Systems, Inc, a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results – that were announced yesterday – used a form of selenium known as selenomethionine. The SELECT TRIAL found no effects of either selenomethionine or vitamin E on the incidence of prostate cancer. See Related Website at cypsystems.com . The results of the SELECT TRIAL are consistent with previous animal studies. For example, Dr. David McCormick at the Experimental Toxicology and Carcinogenesis Division, IIT Research Institute in Chicago found no effects with selenomethionine supplementation on the prevention of prostate cancer in rats (Eur Urol 1999;35:464-467).

Such negative findings have not been observed for other forms of selenium. For example, research at Purdue University found SelenoExcell(R) High-Selenium Yeast to be more effective than selenomethionine in the reducing DNA damage in canine prostate cells (Waters et al, J. Natl Cancer Inst (2003); 95:237-240). Researchers at the University of Arizona and Cornell University reported in the Journal of American Medical Association (Clark et al, JAMA, Dec. 25, 1996-vol. 276, No.24).) that regular use of 200 micrograms per day of selenium in the form of SelenoExcell(R) reduced the incidences of lung, colon, and prostate cancers by 50-63%.

Researchers at the Penn State University Cancer Institute found that supplementation with SelenoExcell(R), reduced serum PSA levels, a risk indicator for prostate cancer (El-Bayoumy et al, Cancer Epidemiology Vol. 11, 1459-1465, Nov., 2002). References to these and other studies can be found at the website, http://www.cypsystems.com – under the research matrix “Cancer” section of the home page.

Paul A. Willis, CEO & President of Cypress Systems, Inc. stated that “Clearly we believe that the SELECT TRIAL should have included the standardized high-selenium yeast, which has been found effective in reducing cancer risk in animal studies and human clinical trials.” High-selenium yeast is different from selenomethionine. It contains several different forms of organically-bound selenium in addition to selenomethionine.

According to Dr. Mark Whitacre, Cypress Systems’ COO, “We suspect that the advantage of SelenoExcell(R) High-Selenium Yeast lies in its content of multiple forms of selenium, including some that are more direct acting in anti-carcinogenesis.”

[tags]Cypress Systems Inc, SELECT TRIAL results, selenium, selenomethionine, SelenoExcell Yeast[/tags]

About Aria Munro

ABOUT THE EDITOR: Aria C. Munro works in the book publishing industry and has been a content editor for the Neotrope News Network since 2004. Her black video iPod is most often shuffling Invader Zim episode vids and Thomas Dolby or Dead Can Dance tunez.

Web | More Posts (3936)

Some rights reserved - attribution required Copr. © 2008 eNewsChannels™ and Aria Munro.
Related Topics: California, News: Pharma, Newsdesk.

Permalink for this story: http://enewschannels.com/2008/11/02/enc4693_155654.php
Important Note: for questions or clarification about any information in the above news item or article, contact the company mentioned in the story and NOT this website. This online publication, eNewsChannels™, cannot assist you with information regarding any person, product, company or opinion expressed or mentioned in the above news story. [323 views]
SIMILAR NEWS CONTENT:
Comments Off

Comments are closed for this story, sorry. Please provide any feedback to the company(s) mentioned in the above story or press release.


IMPORTANT NOTE: All feedback and comments are moderated and will not appear automatically. Any self-promotional or inappropriate remarks, and/or advertising URLs, will be removed and your entry will be submitted to Akismet for spam abuse tracking.

eNewsChannels Categories:
Popular Topics by Content and Search
Neotrope®
News Network